secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001493152-24-045371
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa Q3 net loss $2.4M, cash only $0.1M; Phase 2a trial expected Q1 2025
---------------------------------------------------------------------------

- Net loss improved 17.3% to $2.4M from $2.9M YoY; R&D and G&A expenses decreased.
- Cash at Sept 30, 2024: $0.1M; company will need additional financing on a month-to-month basis.
- Phase 2a trial for VAR 200 in diabetic kidney disease expected to begin Q1 2025 with data mid-2025.
- IC 100 IND submission planned for Q2 2025; Phase 1 trial in overweight subjects planned Q2/Q3 2025.
- Raised ~$3.9M from Q3 2024 to present; formed new Obesity, Metabolic & Inflammatory Disease SAB.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315224045371/0001493152-24-045371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315224045371/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-045371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer